2024
Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study
Petrakis I, Nolen T, Vandergrift N, Hirsch S, Krystal J, De Vivo M, Sabados J, Pisani E, Newcomb J, Kosten T. Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study. American Journal On Addictions 2024 PMID: 39152094, DOI: 10.1111/ajad.13637.Peer-Reviewed Original ResearchPathophysiology of posttraumatic stress disorderAlcohol use disorderSubjective effects of alcoholEffects of alcoholUse disorderComorbid alcohol use disorderAlcohol cue reactivityPosttraumatic stress disorderCrossover laboratory studyCue reactivityAlcohol cravingNoradrenergic dysregulationStress disorderBlood pressureSubjective effectsEthanol administrationClinically significant adverse effectsPharmacotherapeutic approachesTest daysReceptor agonistsPotential treatmentDouble-blind fashionCravingDrinking alcoholDisorders
2003
Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia
Petrakis IL, O’Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH, VA Naltrexone Study Collaboration Group. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 2003, 172: 291-297. PMID: 14634716, DOI: 10.1007/s00213-003-1658-9.Peer-Reviewed Original ResearchConceptsFederal Drug AdministrationSide effectsDrinking daysAlcohol dependenceDouble-blind fashionEfficacy of naltrexoneAbnormal involuntary movementsComorbid alcohol dependenceHeavy drinking daysTreatment of alcoholismSymptoms of schizophreniaRelapse prevention strategiesNegative Symptom ScaleNaltrexone augmentationTime-line follow-back methodNeuroleptic medicationNeuroleptic treatmentEffective medicationsMedication complianceComorbid schizophreniaOutpatient studyWeekly therapyEffective pharmacotherapyConclusionsThese dataInvoluntary movements
2001
Effect of Tryptophan Depletion on Alcohol Cue‐Induced Craving in Abstinent Alcoholic Patients
Petrakis I, Trevisan L, Boutros N, Limoncelli D, Cooney N, Krystal J. Effect of Tryptophan Depletion on Alcohol Cue‐Induced Craving in Abstinent Alcoholic Patients. Alcohol Clinical And Experimental Research 2001, 25: 1151-1155. PMID: 11505046, DOI: 10.1111/j.1530-0277.2001.tb02329.x.Peer-Reviewed Original ResearchConceptsCue-induced cravingAlcohol-dependent patientsTryptophan depletionAlcohol cue-induced cravingDouble-blind fashionPlasma free tryptophanAbstinent alcoholic patientsAmino acid drinkActive tryptophan depletionAlcoholic patientsSerotonin synthesisAcid drinkSober alcoholicsAlcoholic individualsPrecursor tryptophanCue exposurePatientsAlcohol useAbstinent alcoholic individualsCravingFree tryptophanAlcohol cuesTest dayGreater increaseSimilar drinksMethadone patients exhibit increased startle and cortisol response after intravenous yohimbine
Stine S, Grillon C, Morgan III C, Kosten T, Charney D, Krystal J. Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine. Psychopharmacology 2001, 154: 274-281. PMID: 11351934, DOI: 10.1007/s002130000644.Peer-Reviewed Original ResearchConceptsMethadone-maintained patientsAcoustic startle responseCortisol levelsMethadone patientsMHPG levelsAnalysis of covarianceLower baseline plasma levelsStartle responseBaseline plasma cortisol levelsOpioid agonist maintenanceBrain noradrenergic systemCortisol serum levelsDouble-blind fashionBaseline plasma levelsMethadone-maintained subjectsWithdrawal-like symptomsPlasma cortisol levelsPrevious reportsIntravenous yohimbineMethadone effectsOpioid withdrawalSerum levelsNoradrenergic mechanismsOpioid dependenceYohimbine effect
1997
Noradrenergic and Serotonergic Function in Posttraumatic Stress Disorder
Southwick SM, Krystal JH, Bremner JD, Morgan CA, Nicolaou AL, Nagy LM, Johnson DR, Heninger GR, Charney DS. Noradrenergic and Serotonergic Function in Posttraumatic Stress Disorder. JAMA Psychiatry 1997, 54: 749-758. PMID: 9283511, DOI: 10.1001/archpsyc.1997.01830200083012.Peer-Reviewed Original ResearchConceptsYohimbine-induced panic attacksPosttraumatic stress disorderPanic attacksCardiovascular effectsCardiovascular measurementsStress disorderYohimbine hydrochloridePTSD symptomsDiastolic blood pressureDouble-blind fashionSeparate test daysGreater increaseBlood pressureIntravenous infusionSerotonergic functionNoradrenergic activitySerotonergic systemNoradrenergic systemHealthy subjectsSerotonergic activityPatientsDifferent patientsTest dayCombat veteransYohimbinePositron Emission Tomography Measurement of Cerebral Metabolic Correlates of Yohimbine Administration in Combat-Related Posttraumatic Stress Disorder
Bremner JD, Innis RB, Ng CK, Staib LH, Salomon RM, Bronen RA, Duncan J, Southwick SM, Krystal JH, Rich D, Zubal G, Dey H, Soufer R, Charney DS. Positron Emission Tomography Measurement of Cerebral Metabolic Correlates of Yohimbine Administration in Combat-Related Posttraumatic Stress Disorder. JAMA Psychiatry 1997, 54: 246-254. PMID: 9075465, DOI: 10.1001/archpsyc.1997.01830150070011.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderAdministration of yohimbineNorepinephrine releaseHealthy subjectsHealthy age-matched control subjectsAge-matched control subjectsStress disorderDouble-blind fashionPositron emission tomography (PET) measurementsBrain metabolic responsesCerebral metabolic correlatesBrain norepinephrine releaseSymptoms of anxietyPositron emission tomographyBrain metabolismControl subjectsYohimbine administrationPreclinical studiesMetabolic correlatesCaudate nucleusPatientsYohimbineVietnam combat veteransEmission tomographyOrbitofrontal cortex
1990
Specificity of Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder: Comparison of Fluvoxamine and Desipramine
Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS. Specificity of Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder: Comparison of Fluvoxamine and Desipramine. JAMA Psychiatry 1990, 47: 577-585. PMID: 2112374, DOI: 10.1001/archpsyc.1990.01810180077011.Peer-Reviewed Original ResearchConceptsSerotonin reuptake inhibitorsObsessive-compulsive disorderReuptake inhibitorsComparison of fluvoxamineSerotonin receptor functionDouble-blind fashionGlobal response rateWeeks of treatmentBaseline depressive symptomsYale-Brown Obsessive Compulsive ScaleMechanism of actionObsessive Compulsive ScaleReuptake inhibitionDopaminergic functionPrincipal diagnosisDepressive symptomsResponse rateFluvoxamineDesipramineReceptor functionObsessive-compulsive symptomsDesipramine hydrochlorideCompulsive ScaleSymptomsFluvoxamine maleate